跳至主要内容
临床试验/NL-OMON50820
NL-OMON50820已完成不适用

Evaluating the effect of zolpidem and suvorexant in healthy elderly volunteers on walking (adapt)ability. - Evaluating the effect of zolpidem and suvorexant on walking ability.

Centre for Human Drug Research0 个研究点目标入组 18 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Male and female subjects aged between 65 years and 80 years (inclusive) at
  • 2. Body mass index (BMI) within the range of 18 to 30 kg/m2 (inclusive) at
  • 3. Systolic blood pressure 100-160 mmHg, diastolic blood pressure 50-95 mmHg,
  • and pulse rate 45-100 bpm (inclusive), measured on either arm, after 5 min in
  • the supine position at screening.
  • 4. Estimated creatinine clearance (using the Cockcroft &Gault formula) *60
  • mL/min to allow for some reduced renal function in the elderly.
  • 5. Subject has a regular sleep pattern (bedtime between 22:00 and 00:30 and
  • sleep for at least 6 h).

排除标准

  • 1. Hypersensitivity to benzodiazepines and/ or meeting contraindication
  • criteria for zolpidem: myasthenia gravis, sleep apnea syndrome, liver failure,
  • respiratory depression.
  • 2. Hypersensitivity to orexin antagonist and/ or meeting contraindication
  • criteria for suvorexant: narcolepsy.
  • 3. Regular use of sedative/hypnotic drugs.
  • 4. Regular use of walking aids.
  • 5. Recurrent fallers defined as > 3 falls per year.
  • 6. Neurological diseases and/or orthopedic problems interfering with gait
  • 7. Mini Mental State Examination score < 25 at Screening.
  • 8. Current or previous diagnosis of insomnia-related disorder according to the
  • Diagnostic and Statistical Manual of Mental Disorders version 5 (DSM-5)
  • 9. Vaccination for SARS-CoV-2 within 4 days of screening and/or dosing with
  • study drug.

研究者

相似试验